Gastroenterology · Chronic Anal FissureTrial Updateclinicalmid-term

Trial Comparing Botox Alone vs Combined Treatment for Chronic Anal Fissure

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/27/2026, 6:30:56 AM

Assessment confidence: 68% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The trial comparing Botox alone versus combined treatment for chronic anal fissure could significantly impact clinical practice and treatment guidelines. Positive results for the combined approach may enhance Botox's competitive positioning against surgical options, influencing market dynamics. Regulatory context from MHRA (ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly) supports the near-term read. Assessment grounded in 20 ranked evidence items (10 high-relevance).

Strategic Assessment

If combined treatment shows superior outcomes, it could shift clinical practice and affect market dynamics for Botox and surgical interventions. The strongest clinical anchor is Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure (ClinicalTrials.gov), entity match (botox). In Gastroenterology · Chronic Anal Fissure, 5 regulatory and 2 competitive items passed relevance filtering for Botox.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated. The results may influence treatment protocols and competitive positioning of Botox in managing chronic anal fissures against surgical options.

Regulatory Outlook

Regulatory risk is concentrated around ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly (MHRA). Regulatory pathway relevance (nda). Relevant agencies in corpus: MHRA, FDA. The trial's outcomes are unlikely to directly affect regulatory approvals or compliance, but they may inform future labeling and treatment recommendations.

Key Opportunities

If the combined treatment demonstrates superior outcomes, it could lead to increased adoption of Botox, potentially affecting market share and revenue from chronic anal fissure treatments.
Upside for Botox may improve if A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Botox may improve if Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. (PubMed) delivers favorable follow-through.
If combined treatment shows superior outcomes, it could shift clinical practice and affect market dynamics for Botox and surgical interventions.

What Would Change This Assessment

This becomes more urgent if Monitor the trial's completion and results for insights on healing rates and patient satisfaction.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
MHRAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Lower dose needle-free allergy treatment approved for younger children
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds - 08/25/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govhigh relevance
Entity match (botox)
FDA document
View source
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
ClinicalTrials.govhigh relevance
Entity match (botox)
FDA document
View source
Comparison of HF10 Therapy Combined With CMM to CMM Alone in the Treatment of Non-Surgical Refractory Back Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Shock Wave Treatment in Patients With Knee Osteoarthritis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MeDe Study: Comparing Median Nerve Decompression at the Carpal Tunnel Alone Versus Median Nerve Decompression at Both the Carpal Tunnel and Lacertus Fibrosis in Adults With Carpal Tunnel Syndrome
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated
Humanexa Signalsmedium relevance
Moderate corpus alignment

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Observation of the therapeutic effect of flunarizine capsules combined with the Epley manoeuvre in the treatment of benign paroxysmal positional vertigo.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Associations between Age, Treatment Modality and Survival in Atypical Meningioma: Analysis of the SEER Database, 2000-2021.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Botox
chronic anal fissure treatment protocols

Commercial impact

medium

If the combined treatment demonstrates superior outcomes, it could lead to increased adoption of Botox, potentially affecting market share and revenue from chronic anal fissure treatments.

Regulatory impact

low

The trial's outcomes are unlikely to directly affect regulatory approvals or compliance, but they may inform future labeling and treatment recommendations.

What to watch

Monitor the trial's completion and results for insights on healing rates and patient satisfaction.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.